Novo Nordisk Gets Rare Sell Rating as Pipeline and Growth Concerns Mount

Analysts cite ziltivekimab’s trial miss, modest Medicare upside and patent risks.

"Ozempic injection pens move along a conveyor at the Novo Nordisk production facilities in Hillerod, Denmark." Credit: Carsten Snejbjerg/Bloomberg

Already have an account? Sign in.